Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.175 AUD 2.94% Market Closed
Market Cap: 185.4m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

-19.6
Current
-3.9
Median
16.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-19.6
=
Enterprise Value
171.1m AUD
/
EBIT
-8.7m AUD
All Countries
Close
Market Cap EV/EBIT
AU
Arovella Therapeutics Ltd
ASX:ALA
183.8m AUD -19.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
734.5B USD 52.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 22.7
US
Johnson & Johnson
NYSE:JNJ
352B USD 15.1
US
Merck & Co Inc
NYSE:MRK
255.8B USD 12.7
CH
Roche Holding AG
SIX:ROG
211.7B CHF 12.3
UK
AstraZeneca PLC
LSE:AZN
165.4B GBP 254.2
CH
Novartis AG
SIX:NOVN
177.1B CHF 13.4
US
Pfizer Inc
NYSE:PFE
153.7B USD 16.2
EBIT Growth EV/EBIT to Growth
AU
Arovella Therapeutics Ltd
ASX:ALA
Average EV/EBIT: 2 011.3
Negative Multiple: -19.6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.6
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
22.7
22%
1
US
Johnson & Johnson
NYSE:JNJ
15.1
9%
1.7
US
Merck & Co Inc
NYSE:MRK
12.7
98%
0.1
CH
Roche Holding AG
SIX:ROG
12.3
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
254.2
32%
7.9
CH
Novartis AG
SIX:NOVN
13.4
17%
0.8
US
Pfizer Inc
NYSE:PFE
16.2
19%
0.9

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-15.9
2-Years Forward
EV/EBIT
-10.2
3-Years Forward
EV/EBIT
-6.5